BLFS · As filed with the SEC
Biolife Solutions balance sheet, by fiscal year
The statement as Biolife Solutions presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD thousands
| USD thousands | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 |
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 33,038 | 95,386 | 35,407 | 19,442 |
| Restricted cash | — | — | 31 | 31 |
| Available-for-sale securities, current portion | 55,889 | 9,198 | 16,288 | 43,260 |
| Accounts receivable, trade, net of allowance for credit losses of $22 and $152 as of December 31, 2025 and December 31, 2024, respectively | 7,953 | 9,168 | 18,657 | 33,936 |
| Inventories | 30,155 | 29,013 | 43,456 | 34,904 |
| Prepaid expenses and other current assets | 9,526 | 5,996 | 6,765 | 6,879 |
| Current assets, discontinued operations | 0 | 0 | — | — |
| Total current assets | 136,561 | 148,761 | 120,604 | 138,452 |
| Assets held for rent, net | — | — | — | 9,064 |
| Assets held for rent, net | — | 6,103 | 7,713 | — |
| Property and equipment, net | 14,713 | 6,084 | 21,077 | 23,638 |
| Operating lease right-of-use assets, net | 7,466 | 10,674 | 11,446 | 15,292 |
| Financing lease right-of-use assets, net | — | — | 94 | 272 |
| Long-term deposits and other assets | — | 379 | 273 | 281 |
| Other assets | 3,050 | — | — | — |
| Available-for-sale securities, long term | 31,250 | 4,628 | 548 | 1,332 |
| Equity Investments | — | — | — | 5,069 |
| Equity Investments | — | — | 5,069 | — |
| Equity investments | 0 | 995 | — | — |
| Intangible assets, net | 4,257 | 9,559 | 21,149 | 32,088 |
| Goodwill | 208,587 | 212,304 | 224,741 | 224,741 |
| Long-term assets, discontinued operations | 0 | 0 | — | — |
| Total assets | 405,884 | 399,487 | 412,714 | 450,229 |
| Liabilities and Shareholders’ Equity | ||||
| Current liabilities: | ||||
| Accounts payable | 1,486 | 3,573 | 6,940 | 15,367 |
| Accrued expenses and other current liabilities | 11,974 | 12,451 | 11,932 | 9,782 |
| Sales taxes payable | 2,279 | 4,256 | 5,442 | 4,151 |
| Warranty liability | — | — | 7,858 | 8,312 |
| Lease liabilities, operating, current portion | 2,243 | 1,511 | 2,797 | 2,860 |
| Lease liabilities, financing, current portion | — | — | 376 | 158 |
| Debt, current portion | 4,997 | 10,943 | 6,833 | 1,814 |
| Contingent consideration, current portion | — | — | 0 | 2,138 |
| Current liabilities, discontinued operations | 0 | 0 | — | — |
| Total current liabilities | 22,979 | 32,734 | 42,178 | 44,582 |
| Contingent consideration, long-term | — | — | 0 | 2,318 |
| Lease liabilities, operating, long-term | 10,657 | 12,723 | 13,205 | 14,962 |
| Lease liabilities, financing, long-term | — | — | 1,169 | 126 |
| Debt, long-term | 0 | 4,997 | 18,311 | 23,793 |
| Deferred tax liabilities | 189 | 124 | 188 | 250 |
| Other long-term liabilities | 171 | — | 0 | 10 |
| Long-term liabilities, discontinued operations | 0 | 0 | — | — |
| Total liabilities | 33,996 | 50,578 | 75,051 | 86,041 |
| Shareholders’ equity: | ||||
| Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | 0 |
| Common stock, $0.001 par value; 150,000,000 shares authorized, 48,198,928 and 46,906,765 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 48 | 47 | 45 | 43 |
| Additional paid-in capital | 711,404 | 683,939 | 651,305 | 611,739 |
| Accumulated other comprehensive loss, net of taxes | 132 | 24 | (345) | (679) |
| Accumulated deficit | (339,696) | (335,101) | (313,342) | (246,915) |
| Total shareholders’ equity | 371,888 | 348,909 | 337,663 | 364,188 |
| Total liabilities and shareholders’ equity | 405,884 | 399,487 | 412,714 | 450,229 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.